63 8

Full metadata record

DC FieldValueLanguage
dc.contributor.author이창범-
dc.date.accessioned2018-05-24T06:49:54Z-
dc.date.available2018-05-24T06:49:54Z-
dc.date.issued2016-05-
dc.identifier.citationDiabetes, Obesity and Metabolism, v. 18, no. 5, Page. 528-532en_US
dc.identifier.issn1462-8902-
dc.identifier.issn1463-1326-
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/abs/10.1111/dom.12631-
dc.identifier.urihttp://repository.hanyang.ac.kr/handle/20.500.11754/71500-
dc.description.abstractWe assessed the 24-week efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus (T2DM) that was inadequately controlled with diet and exercise. The present study was designed as a multicentre, randomized, double-blind, placebo-controlled, parallel-group, phase III study. Patients (n = 142) were randomized 2 : 1 into two different treatment groups as follows: 99 received teneligliptin (20 mg) and 43 received placebo. The primary endpoint was change in glycated haemoglobin (HbA1c) level from baseline to week 24. Teneligliptin significantly reduced the HbA1c level from baseline compared with placebo after 24weeks. At week 24, the differences between changes in HbA1c and fasting plasma glucose (FBG) in the teneligliptin and placebo groups were -0.94% [least-squares (LS) mean -1.22, -0.65] and -1.21 mmol/l (-1.72, -0.70), respectively (all p < 0.001). The incidence of hypoglycaemia and adverse events were not significantly different between the two groups. This phase III, randomized, placebo-controlled study provides evidence of the safety and efficacy of 24weeks of treatment with teneligliptin as a monotherapy in Korean patients with T2DM.en_US
dc.description.sponsorshipThis study was supported by Handok Inc., Seoul, Republic of Korea.en_US
dc.language.isoenen_US
dc.publisherWiley-Blackwellen_US
dc.subjectantidiabetic drugen_US
dc.subjectDPP-IV inhibitoren_US
dc.subjectphase III studyen_US
dc.subjecttype 2 diabetesen_US
dc.titleEfficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trialen_US
dc.typeArticleen_US
dc.relation.volume18-
dc.identifier.doi10.1111/dom.12631-
dc.relation.page528-532-
dc.relation.journalDiabetes, Obesity and Metabolism-
dc.contributor.googleauthorHong, S.-
dc.contributor.googleauthorPark, C. -Y.-
dc.contributor.googleauthorHan, K. A.-
dc.contributor.googleauthorChung, C. H.-
dc.contributor.googleauthorKu, B. J.-
dc.contributor.googleauthorJang, H. C.-
dc.contributor.googleauthorAhn, C. W.-
dc.contributor.googleauthorLee, M. -K.-
dc.contributor.googleauthorMoon, M. K.-
dc.contributor.googleauthorLee, C. B.-
dc.relation.code2016025044-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidlekang-


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE